Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s share price fell 5.9% on Tuesday . The stock traded as low as $2.99 and last traded at $3.01. 2,281,447 shares changed hands during mid-day trading, an increase of 12% from the average session volume of 2,038,004 shares. The stock had previously closed at $3.20.
Several research firms have weighed in on ACHN. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 13th. B. Riley began coverage on shares of Achillion Pharmaceuticals in a report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 target price on the stock. Leerink Swann reiterated a “buy” rating and issued a $5.00 target price on shares of Achillion Pharmaceuticals in a report on Monday, December 11th. Finally, Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.89.
The stock has a market capitalization of $414.95, a P/E ratio of -6.25 and a beta of 1.32.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter last year, the firm earned ($0.03) EPS. research analysts predict that Achillion Pharmaceuticals, Inc. will post -0.6 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC purchased a new stake in shares of Achillion Pharmaceuticals in the 4th quarter valued at approximately $162,000. TIAA CREF Investment Management LLC raised its stake in shares of Achillion Pharmaceuticals by 13.2% in the 4th quarter. TIAA CREF Investment Management LLC now owns 363,571 shares of the biopharmaceutical company’s stock valued at $1,047,000 after acquiring an additional 42,358 shares during the period. Teachers Advisors LLC raised its stake in shares of Achillion Pharmaceuticals by 3.9% in the 4th quarter. Teachers Advisors LLC now owns 1,552,264 shares of the biopharmaceutical company’s stock valued at $4,471,000 after acquiring an additional 57,782 shares during the period. Sarissa Capital Management LP raised its stake in shares of Achillion Pharmaceuticals by 17.0% in the 4th quarter. Sarissa Capital Management LP now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $7,200,000 after acquiring an additional 363,200 shares during the period. Finally, Perceptive Advisors LLC purchased a new stake in shares of Achillion Pharmaceuticals in the 4th quarter valued at approximately $2,880,000. 78.75% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/achillion-pharmaceuticals-achn-stock-price-down-5-9.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.